The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

被引:0
|
作者
Zamani, Farhad [1 ]
Ajdarkosh, Hossein [1 ]
Safarnezhad-Tameshkel, Fahimeh [1 ]
Azarkeivan, Azita [2 ]
Keyvani, Hossein [1 ]
Naserifar, Farshad [1 ]
Vafaeimanesh, Jamshid [1 ,3 ]
机构
[1] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran
[2] Blood Transfus Res Ctr, High Inst Res & Educ Transfus Med, Thalassemia Clin, Pediat Hematol Oncol, Tehran, Iran
[3] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran
关键词
Anaemia; daclatasvir; hepatitis C virus; sofosbuvir; thalassaemia major; ADVANCED LIVER-DISEASE; HCV GENOTYPE 1; VIRUS-INFECTION; PHASE-III; RIBAVIRIN; LEDIPASVIR; COMBINATION; PREVALENCE; CIRRHOSIS; NAIVE;
D O I
10.4103/ijmm.IJMM_18_90
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Context: Patients with thalassaemia arc at risk of infections such as hepatitis C virus (HCV) due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients who had developed HCV infection is a controversial issue. Aims: Although the effectiveness of direct-acting anti virals on HCV infection has been confirmed, their side-effects as well as effects on haematological factors due to the resultant need for blood transfusion remain to be further understood. Materials and Methods: In this study, 61 patients with major beta thalassaemia and HCV infection, and who had a history of interferon treatment failure were examined. The patients underwent a 24-week treatment with sofosbuvir (SOF) and daclatasvir (DAC). Sustained virological response 12 was used to assess response to treatment. At the end of the study, the need for blood transfusion and serum terrain was evaluated. Results: About 98.4% of the patients responded to the treatment, and only one patient with genotype 1b did not respond positively. No significant complications necessitating treatment cessation were observed, and all the patients tolerated the treatment well. The level of liver enzymes showed a significant reduction 12 weeks after the treatment. The need for blood transfusions in patients before treatment was averagely 1.595 +/- 0.65 bag per month, in which 1.593 +/- 0.64 bags were received after treatment (P = 0.9). This regimen did not affect the amount of anaemia in patients and did not differentiate the need for blood transfusions. The rate of haemoglobin before treatment was 9.5 +/- 1.42 g/dl, which reached 9.6 +/- 1.6 g/dl after treatment (P = 0.54). Ferritin levels decreased significantly (from 1948.08 +/- 1539.54 to 1315.73 +/- 1207.67 ng/ml) (P = 0.001) in the patients after the treatment. Conclusion: Combination of SOF and DAC is an effective and tolerable treatment regimen without affect on the amount of anaemia in patients and did not differentiate the need for blood transfusions.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [21] Daclatasvir plus asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison
    Swallow, Elyse
    Kelley, Caroline
    Signorovitch, James
    Wygant, Gail
    McPhee, Fiona
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (03) : 273 - 279
  • [22] Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
    Butt, Nazish
    Abbasi, Amanullah
    Khan, M. Ali
    Ali, Muhammad
    Mahesar, Ghulam B.
    Haleem, Farhan
    Manan, Abdul
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (09)
  • [23] Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection
    Yakoot, Mostafa
    El-Shabrawi, Mortada H.
    AbdElgawad, Manal M.
    Mahfouz, Aml A.
    Helmy, Sherine
    Abdo, Alaa M.
    El-Khayat, Hisham R.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (01) : 86 - 89
  • [24] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
    Shiha, G.
    Soliman, R.
    ElBasiony, M.
    Hassan, A. A.
    Mikhail, N. N. H.
    HEPATOLOGY INTERNATIONAL, 2018, 12 (04) : 339 - 347
  • [25] Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
    Coilly, Audrey
    Fougerou-Leurent, Claire
    de Ledinghen, Victor
    Houssel-Debry, Pauline
    Duvoux, Christophe
    Di Martino, Vincent
    Radenne, Sylvie
    Kamar, Nassim
    D'Alteroche, Louis
    Leroy, Vincent
    Canva, Valerie
    Lebray, Pascal
    Moreno, Christophe
    Dumortier, Jerome
    Silvain, Christine
    Besch, Camille
    Perre, Philippe
    Botta-Fridlund, Danielle
    Anty, Rodolphe
    Francoz, Claire
    Aberge, Armando
    Debette-Gratien, Maryline
    Conti, Filomena
    Habersetzer, Francois
    Rohel, Alexandra
    Rossignol, Emilie
    Danjou, Helene
    Roque-Afonso, Anne-Marie
    Samuel, Didier
    Duclos-Vallee, Jean-Charles
    Pageaux, Georges-Philippe
    JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 711 - 718
  • [26] Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation
    Omichi, Kiyohiko
    Akamatsu, Nobuhisa
    Mori, Kazuhiro
    Togashi, Junichi
    Arita, Junichi
    Kaneko, Junichi
    Hasegawa, Kiyoshi
    Sakamoto, Yoshihiro
    Kokudo, Norihiro
    HEPATOLOGY RESEARCH, 2017, 47 (11) : 1093 - 1101
  • [27] Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study
    Elbedewy, Tamer A.
    Abd-Elsalam, Sherief
    Mostafa, Sahar Mohamed
    Abdellatif, Raghda Samir
    Fouad, Amina
    Youssef, Mona
    Abo-Amer, Yousry Esam-Eldin
    Elsebaey, Mohamed A.
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2022, 22 (03) : 290 - 296
  • [28] Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
    Polo Gascon, Maria Rita
    Guerra Benute, Glaucia Rosana
    Macedo, Elizeu Coutinho
    Capitao, Claudio Garcia
    Vidal, Jose Ernesto
    Smid, Jerusa
    Nascimento Marcusso, Rosa Maria
    Souza de Lucia, Mara Cristina
    Penalva-de-Oliveira, Augusto Cesar
    Diament, Decio
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2020, 78 (06) : 342 - 348
  • [29] Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation
    Leroy, Vincent
    Dumortier, Jerome
    Coilly, Audrey
    Sebagh, Mylene
    Fougerou-Leurent, Claire
    Radenne, Sylvie
    Botta, Danielle
    Durand, Francois
    Silvain, Christine
    Lebray, Pascal
    Houssel-Debry, Pauline
    Kamar, Nassim
    D'Alteroche, Louis
    Petrov-Sanchez, Ventzislava
    Diallo, Alpha
    Pageaux, Georges-Philippe
    Duclos-Vallee, Jean-Charles
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) : 1993 - +
  • [30] Effectiveness and Safety of Sofosbuvir in Treatment-Naive Children with Hepatitis C Infection
    Hashmi, Muhammad Almas
    Cheema, Huma Arshad
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2017, 27 (07): : 423 - 426